Bio-Works Technologies AB is pleased to announce that it has received a Letter of Intent (LOI) for a significant order of WorkBeads™ affimAb, used in manufacturing processes of vaccines. The anticipated order value is €652,000.
This LOI marks a pivotal step toward reinforcing Bio-Works’ relationship with our customers in the biopharmaceutical industry. Bio-Works’ WorkBeads affimAb product has shown exceptional value in high-stakes manufacturing environments, with data from multiple manufacturing sites affirming its performance.
“We are thrilled about the potential of this order, as it underscores the trust and value placed in Bio-Works’ products by industry leaders” said Lone Carlbom, CEO of Bio-Works. “This LOI is a testament to our commitment to quality and innovation, and we look forward to further strengthening our partnerships across the biopharmaceutical sector.”
Contacts
For more information, please visit the Bio-Works homepage at, www.bio-works.com or contact: Lone Carlbom, CEO, e-mail: lone.carlbom@bio-works.com, phone: +46(0)8-502 705 84.
About Bio-Works
Bio-Works enables Biotech companies to achieve their goals for purification of biomolecules. We support our customers, from laboratory research to commercial production, and together we implement efficient and robust solutions for bioprocessing. Our ambition is to be a trusted and dynamic partner in an industry characterized by growth and development.
Bio-Works’ headquarters, with R&D and manufacturing, is located in Uppsala Business Park in Uppsala, Sweden. We supply products globally, through a combination of direct sales and via distributors in Europe, North America and Asia. The company is certified according to the ISO 9001:2015 quality management system. Bio-Works is listed on Spotlight Stock Market (“BIOWKS”). For more information, visit www.bio-works.com.
